Decision to list medical devices in the interventional radiology category supplied by Becton Dickinson Limited
9 December 2019
What we are doing
We are pleased to announce the approval of a listing agreement with Becton Dickinson Limited (“BD”) for the supply of interventional radiology medical devices to DHBs.
In summary this will result in:
- BD’s devices being listed in Part III of the Section H of the Pharmaceutical Schedule from 1 February 2020 under a national agreement that all DHBs may purchase under (“Agreement”);
- DHBs being able to continue to purchase other suppliers’ brands of interventional radiology devices.
Any changes to the original proposal?
There were no changes to the agreement following consultation feedback.
Who we think will be most interested
- DHB staff
- Interventional radiology clinical staff
- Procurement and supply chain personnel
- Suppliers and Wholesalers
Detail about this decision
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation processes, and consulting on the provisional Agreement reached with BD, PHARMAC has decided to list BD’s medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020. This is the final agreement for the interventional radiology category.
DHBs can continue to choose which interventional radiology devices they purchase, including those from other suppliers. DHBs that purchase interventional radiology devices from BD, must do so under the terms and conditions, including pricing, in the Agreement, from 1 February 2020.
The agreement includes terms and conditions for training and education to be provided by BD on the appropriate use of its products, which will be tailored to the needs of individual DHBs.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
Advising no technical resource impacts anticipated as a result of the proposal.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 July 2020